Joshua Levin is a research scientist II, group leader in the Broad Institute’s Stanley Center for Psychiatric Research, as well as in the Klarman Cell Observatory at the Broad Institute. Over the last six years, he has developed and comprehensively evaluated a broad portfolio of RNA sequencing (RNA-Seq) methods such as targeted, strand-specific, total, and low-input RNA-Seq protocols. These RNA-Seq methodologies are being used for a variety of projects institute-wide, notably cancer transcriptomics, single cell studies, and genome annotation. Levin has also established next-generation sequencing methods for RNA viruses including HIV, West Nile virus, and Lassa virus.
Before joining the Broad, Levin worked for ten years in the biotechnology industry, first at Syngenta (formerly Ciba-Geigy & Novartis) and then at Novartis Pharmaceuticals using model organisms in functional genomics studies.
Levin received his B.A. in biochemistry from the University of Pennsylvania and his Ph.D. in biology in the laboratory of Robert Horvitz at MIT.